Download MendeleyStructure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2.
Schevitz, R.W., Bach, N.J., Carlson, D.G., Chirgadze, N.Y., Clawson, D.K., D Dillard, R., Draheim, S.D., Hartley, L.W., Jones, N.D., Mihelich, E.D., L Olkowski, J., Snyder, D.W., Dand, S.C., Wery, J.-P.(1995) Nat Struct Biol 2: 458-465
- PubMed: 7664108
- DOI: https://doi.org/10.1038/nsb0695-458
- Primary Citation of Related Structures:
1DB4, 1DB5, 1DCY - PubMed Abstract:
A lead compound obtained from a high volume human non-pancreatic secretory phospholipase A2 (hnps-PLA2) screen has been developed into a potent inhibitor using detailed structural knowledge of inhibitor binding to the enzyme active site. Four crystal structures of hnps-PLA2 complexed with a series of increasingly potent indole inhibitors were determined and used as the structural basis for both understanding this binding and providing valuable insights for further development. The application of structure-based drug design has made possible improvements in the binding of this screening lead to the enzyme by nearly three orders of magnitude. Furthermore, the optimized structure (LY311727) displayed 1,500-fold selectivity when assayed against porcine pancreatic s-PLA2.
Organizational Affiliation:
Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
